Say hello to our new logo!

Since its establishment, SanegeneBio has achieved rapid growth. In 2024, this will be a new chapter in our development. Today we're launching a new logo.

The new logo is based on the initial letters "S" and "g" of the company name "Sanegene" and revolves around the core concept of "innovation, pioneering and responsibility". We believe that gene, sail and white dove can interpret our brand image. At the same time, we use brighter blue and red to convey our notion that we are not only technological and rigorous, but also energetic and warm. The new logo presents the core value of SanegeneBio in a more intuitive manner, vividly reflecting SanegeneBio's vision of "Realize full potential of RNAi technology. Bring life-changing RNA medicines to reality".

About SanegeneBio

SanegeneBio is an emerging RNAi-based company developing innovative RNA interference (RNAi) therapeutics driven by the cutting-edge delivery technology. Founded in 2021, SanegeneBio was led by a team of industry-leading experts and has operations in both the US and China. Since its incorporation, SanegeneBio has successfully established proprietary chemical modification platform, hepatic and extrahepatic delivery platforms, enabling tissue-specific delivery of a wide range of RNA therapeutics to efficiently knock down disease-causing genes. Our fast-growing RNAi portfolio covers a broad range of therapeutic areas including cardiovascular and metabolic diseases, immunology-related diseases, and nervous system diseases. Among them, our three RNAi drugs have entered into the clinical stage, and several pipelines are in progress simultaneously. SanegeneBio is committed to developing transformational RNAi medicines through striving for scientific innovation to address unmet medical needs worldwide and change the lives of patients and families. For further information, please visit: www.sanegenebio.com  and engage with us on LinkedIn.